The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
AstraZeneca to establish partnership for new R&D center in Beijing
Mar 21, 2025•about 1 year ago
Contract Type
partnership
Cambridge
Description
AstraZeneca has announced a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office to invest $2.5 billion in Beijing. This investment will establish the company's sixth global strategic R&D center, and includes agreements with three biotech companies. The partnership reflects AstraZeneca's commitment to the life sciences ecosystem in Beijing and its dedication to bringing innovative medicines to patients worldwide.
Company Information
Company
British biopharma company
Location
Cambridge, Massachusetts, United States
About
A British biopharmaceutical company focused on developing new therapies and treatments for various diseases. The company is known for its expertise in drug development and innovative approaches to healthcare. It aims to address unmet medical needs through advanced biopharmaceutical solutions. Details on its specific operations or pipeline are not provided in the current context.
Cambridge